Pregabalin add-on for drug-resistant partial epilepsy

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Pulman, Jennifer ^a   Hemming, Karla ^b   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; PLACEBO; PREGABALIN; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ADD ON THERAPY; ADVERSE OUTCOME; ATAXIA; BODY WEIGHT GAIN; DIZZINESS; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOMNOLENCE; SYSTEMATIC REVIEW; DRUG RESISTANCE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSIES, PARTIAL; GAMMA-AMINOBUTYRIC ACID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907388068     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005612.pub3     Document Type: Review

References (21)

1. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al.Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45(1):20-7. [: CN-00453016]
2. Baulac M, Leon T, O'Brien T, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Research 2010;1(91):10-9. [: CN-00769723]
3. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64(3):475-80. [: CN-00508438]
4. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005;46(12):1926-36. [: CN-00532656]
5. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60(10):1631-7. [: CN-00431856]
6. Lee BI, Yi S, Hong SB, Kim MK, Lee SA, Lee SK, et al.Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 2009;50(3):464-74. [: CN-00688320]
7. Russi A, Tarancon T. Comparative dosage adjustment of levetiracetam and pregabalin as adjunctive therapy for refractory partial epilepsy with polytherapy. A prospective observational randomized study. Epilepsia 2006;47(Suppl 4):172.
8. Tata M, Guizzaro A, Daniele O, Natale E. Open label, randomised, cross-over trial in epilepsy patients with cryptogenic focal, refractory epilepsy, comparing levetiracetam and pregabalin as add-on therapy. Epilepsia 2007;484(Suppl 7):69-70.
9. Bakhshandeh Bali MK. Comparisson of the effect of Zonisamide and Pregabalin as adjunctive therapy in control of interactable epilepsy in children. Iranian Registry of Clinical Trials 2012.
10. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, et al.Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13.
11. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4.
12. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al.Inhibition of neuronal (Ca2+) influx by gabapentin and pregabalin in human neocortex. Neuropharmacology 2002;42(2):229-36.
13. Hauser WA, Hesdorffer DC. Epilepsy: Frequency, Causes and Consequences. New York: Demos Publications, 1990.
14. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd, 2011.
15. Commission on Antiepileptic Drugs of the International League Against Epilepsy. Guidelines for clinical evaluation of antiepileptic drugs. Epilepsia 1989;30(4):400-8.
16. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al.The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:365.
17. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19:3417-32.
19. Villeneuve N. [Quality-of-life scales for patients with drug-resistant partial epilepsy]. Reviews of Neurology (Paris) 2004;160(Spec No.1):5S376-93.
20. Lozsadi D, Bate L, Hutton JL, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005612]
21. Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD005612.pub2]